[시장보고서]전신성 소아특발성관절염 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별 부문(2020-2030F)

전신성 소아특발성관절염 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별 부문(2020-2030F)

Systemic Juvenile Idiopathic Arthritis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

상품코드 : 1703266

리서치사 : TechSci Research

발행일 : 2025년 04월

페이지 정보 : 영문 183 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,699,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,188,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,910,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 전신성 소아특발성관절염(sJIA) 시장은 2024년에 18억 3,000만 달러로 평가되고, 예측 기간 중 4.61%의 연평균 성장률(CAGR)을 기록하며, 2030년까지 24억 달러에 달할 것으로 예측됩니다.

이 시장은 소아특발성관절염의 희소 및 심도 서브타입인 전신성 JIA의 개발, 진단, 치료, 관리를 포괄하고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	18억 3,000만 달러
시장 규모 : 2030년	24억 달러
CAGR : 2025-2030년	4.61%
급성장 부문	온라인 약국
최대 시장	북미

sJIA는 전신 염증, 고열, 피부 발진, 관절통, 장기 손상을 포함한 합병증 발생 가능성이 있는 복잡한 자가면역질환으로 주로 소아에게 발병하는 질환입니다. 이 시장은 환자의 예후와 삶의 질을 개선하기 위한 의약품, 생물제제, 의료기기, 지지요법 전략 등 광범위한 치료 솔루션에 걸쳐 있습니다.

주요 시장 성장 촉진요인

생물제제의 진보

주요 시장이 해결해야 할 과제

높은 치료비

주요 시장 동향

맞춤형 의료

시장 규모·예측
- 금액별
시장 점유율·예측
- 치료의 유형별(약물 치료(항염증약(NSAID), 종양괴사인자(TNF) 저해제, 근이완약, 면역억제제, 질환 조절성 항류머티즘약, 기타), 생물제제, 기타)
- 투여 경로별(경구, 주사, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 기업별(2024)
- 지역별
시장 맵

제6장 북미의 전신성 소아특발성관절염 시장 전망

시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
- 미국
- 멕시코
- 캐나다

제7장 유럽의 전신성 소아특발성관절염 시장 전망

시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
- 프랑스
- 독일
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 전신성 소아특발성관절염 시장 전망

시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 한국
- 일본
- 호주

제9장 남미의 전신성 소아특발성관절염 시장 전망

시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 전신성 소아특발성관절염 시장 전망

시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트

제11장 시장 역학

촉진요인
과제

제12장 시장 동향과 발전

최근 동향
제품 출시
합병과 인수

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협

제15장 경쟁 구도

Novartis AG
Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Bristol-Myers Squibb Company
Cadila Healthcare Ltd.
Genetech, Inc.
LATAM Pharma
Alteogen Inc.
Johnson & Johnson
Momenta Pharmaceuticals, Inc.

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.40 billion by 2030, registering a compound annual growth rate (CAGR) of 4.61% during the forecast period. This market encompasses the development, diagnosis, treatment, and management of systemic JIA-a rare and severe subtype of juvenile idiopathic arthritis.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.83 Billion
Market Size 2030	USD 2.40 Billion
CAGR 2025-2030	4.61%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

sJIA is a complex autoimmune condition primarily affecting children and is marked by systemic inflammation, high fevers, skin rashes, and joint pain, with potential complications including organ damage. The market spans a broad spectrum of therapeutic solutions, including pharmaceuticals, biologics, medical devices, and supportive care strategies aimed at improving patient outcomes and quality of life.

Key Market Drivers

Advancements in Biologic Therapies

The increasing global burden of chronic autoimmune diseases is a key contributor to the growth of the sJIA market. Although systemic JIA is a rare pediatric autoimmune condition, it benefits from broader developments in autoimmune disease research and treatment.

According to a study published in Frontiers in Immunology (PMC9918670), the incidence of autoimmune diseases has increased by 19.1%, with a 12.5% rise in prevalence annually. This trend has intensified global focus and investment in autoimmune research, accelerating the development of new treatment approaches for conditions such as sJIA.

Research into more common autoimmune disorders-such as lupus and rheumatoid arthritis-has uncovered shared immunological pathways that are informing the development of novel and repurposed therapies for sJIA. Healthcare systems are also shifting toward integrated, patient-centered chronic disease management models, prioritizing early diagnosis, personalized care plans, and coordinated treatment approaches.

In the United States, the CDC reports that approximately 220,000 children and adolescents live with arthritis-related conditions, including sJIA (MMWR Morb Mortal Wkly Rep 2023;72:793-798). This growing pediatric population is prompting improved screening and referral systems, which in turn are enhancing early detection and treatment outcomes.

Pharmaceutical companies are responding to this demand by investing heavily in biologics and other targeted therapies specifically designed for pediatric autoimmune conditions. These innovations are reshaping the treatment landscape, improving clinical outcomes, and enhancing quality of life for affected children.

Key Market Challenges

High Treatment Costs

One of the most significant barriers to effective care in the Global sJIA Market is the high cost associated with treatment. Managing sJIA typically involves a comprehensive, multidisciplinary approach, including medications to control systemic inflammation and prevent long-term complications.

A major cost driver is the use of biologic therapies, particularly IL-1 and IL-6 inhibitors, which have proven highly effective in treating sJIA. However, these advanced biologics are among the most expensive drugs on the market and often require long-term administration, leading to a substantial financial burden for patients and healthcare systems.

Beyond the cost of medications, managing sJIA often involves routine monitoring, imaging studies, physical therapy, and consultations with multiple specialists. These ancillary costs can further strain healthcare budgets and impose significant financial challenges on families.

Key Market Trends

Personalized Medicine

Personalized medicine is increasingly shaping the future of the sJIA market by offering more tailored and effective treatment approaches based on an individual's genetic, molecular, and clinical profile. This patient-specific strategy is helping optimize therapeutic outcomes while reducing risks associated with traditional trial-and-error treatment methods.

In sJIA care, the use of advanced molecular and genetic profiling tools enables clinicians to better understand disease mechanisms and identify actionable molecular targets. This facilitates the development of highly specialized treatment plans that address the unique disease pathways of each patient.

A key advantage of personalized medicine is its predictive capability-allowing healthcare providers to determine which patients are most likely to respond favorably to specific biologics or immunosuppressive therapies. This not only enhances treatment efficacy but also reduces exposure to ineffective medications and associated side effects.

Furthermore, personalized dosing strategies ensure that patients receive the most appropriate therapeutic regimen, enhancing treatment safety and improving overall patient outcomes. As this approach becomes more widely adopted, it is expected to significantly advance the management of sJIA and reinforce the market's growth trajectory.

Key Market Players

Novartis AG
Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Bristol - Myers Squibb Company
Cadila Healthcare Ltd.
Genetech, Inc.
LATAM Pharma
Alteogen Inc.
Johnson & Johnson
Momenta Pharmaceuticals, Inc

Report Scope:

In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type:

Drug Treatment
Biologics
Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration:

Oral
Injectables
Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Systemic Juvenile Idiopathic Arthritis Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.

Available Customizations:

Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other)
- 5.2.2. By Route of Administration (Oral, Injectables, Other)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Company (2024)
- 5.2.5. By Region
5.3. Market Map

6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment Type
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment Type
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Mexico Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment Type
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Canada Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment Type
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Distribution Channel

7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment Type
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment Type
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. Germany Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment Type
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment Type
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment Type
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment Type
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment Type
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment Type
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment Type
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. South Korea Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment Type
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. Japan Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment Type
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment Type
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Distribution Channel

9. South America Systemic Juvenile Idiopathic Arthritis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment Type
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment Type
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment Type
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment Type
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Systemic Juvenile Idiopathic Arthritis Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment Type
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment Type
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment Type
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Systemic Juvenile Idiopathic Arthritis Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment Type
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (In case of listed companies)
- 15.1.5. Recent Developments
- 15.1.6. SWOT Analysis
15.2. Hoffmann-La Roche Ltd
15.3. Takeda Pharmaceutical Company Limited
15.4. Bristol - Myers Squibb Company
15.5. Cadila Healthcare Ltd.
15.6. Genetech, Inc.
15.7. LATAM Pharma
15.8. Alteogen Inc.
15.9. Johnson & Johnson
15.10. Momenta Pharmaceuticals, Inc.